Clinical Trial Update: Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial of daratumumab with lenalidomide, bortezomib, and dexamethasone induction (Dara-RVd) for newly diagnosed multiple myeloma undergoing autologous st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Status: SUSPENDED